Calliditas Therapeutics AB (publ)
CALT · NASDAQ
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|
| Market Cap | $10,996,208 | $6,076,294 | $6,956,328 | $5,350,692 |
| - Cash | $797,278 | $810,317 | $973,733 | $786,883 |
| + Debt | $1,008,272 | $1,016,618 | $979,133 | $770,161 |
| Enterprise Value | $11,207,202 | $6,282,595 | $6,961,728 | $5,333,970 |
| Revenue | $559,780 | $295,481 | $451,561 | $294,592 |
| % Growth | 89.4% | -34.6% | 53.3% | – |
| Gross Profit | $506,332 | $281,469 | $429,262 | $279,671 |
| % Margin | 90.5% | 95.3% | 95.1% | 94.9% |
| EBITDA | -$28,807 | -$202,768 | $32,061 | -$159,046 |
| % Margin | -5.1% | -68.6% | 7.1% | -54% |
| Net Income | -$47,478 | -$246,160 | -$18,368 | -$168,357 |
| % Margin | -8.5% | -83.3% | -4.1% | -57.1% |
| EPS Diluted | -1.76 | -9.18 | -0.68 | -6.28 |
| % Growth | 80.8% | -1,250% | 89.2% | – |
| Operating Cash Flow | -$7,043 | -$198,205 | $22,845 | -$62,529 |
| Capital Expenditures | $0 | $0 | -$12,788 | $0 |
| Free Cash Flow | -$7,043 | -$198,205 | $10,057 | -$62,529 |